Welcome to our dedicated page for Infusystem Hld SEC filings (Ticker: INFU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The InfuSystem Holdings, Inc. (NYSE American: INFU) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a national health care service provider that facilitates outpatient care for durable medical equipment manufacturers and health care providers, InfuSystem uses these filings to report financial results, corporate events and other information relevant to investors.
Among the most frequently referenced documents are current reports on Form 8-K. Recent 8-K filings include press releases reporting quarterly financial results, such as the second and third quarter 2025 earnings releases furnished on August 5, 2025 and November 4, 2025. These filings summarize net revenues, segment performance for the Patient Services and Device Solutions platforms, gross margin, cash flow and Adjusted EBITDA, and often discuss factors like revenue mix and information technology projects.
Other 8-K filings furnish Regulation FD disclosures, including investor presentations and announcements of upcoming earnings release dates and conference calls. For example, filings dated July 29, 2025 and October 28, 2025 describe when InfuSystem will issue financial results and how investors can access related conference calls and webcasts. Additional 8-Ks report participation in investor conferences and provide investor presentation materials as exhibits.
InfuSystem has also used Form 8-K to disclose leadership changes and regulatory developments. A filing dated April 1, 2025 describes a CEO transition and reaffirms financial guidance, while a filing dated December 10, 2025 reports that the Centers for Medicare and Medicaid Services added two electronic infusion pumps used in the company’s Pain Management services business to the list of qualifying products for separate payment under the NOPAIN Act.
On Stock Titan, InfuSystem’s SEC filings are supplemented with AI-powered summaries designed to highlight the key points in lengthy documents, such as annual reports on Form 10-K, quarterly reports on Form 10-Q and detailed 8-K exhibits. These tools can help users quickly identify disclosures related to segment performance, capital expenditures on medical devices, information technology upgrade projects, stock repurchase activity, guidance ranges and other topics discussed by the company in its filings.
Investors can use this page to follow InfuSystem’s formal communications with regulators, track how management describes the performance of the Patient Services and Device Solutions platforms, and review historical filings for context on the company’s operations and strategic direction.
Insider filing for Carrie Lachance, President and CEO of InfuSystem Holdings (INFU). On 09/23/2025, 50,000 performance-based restricted stock units granted May 16, 2025, vested and were settled into common stock. The issuer withheld 19,675 shares to cover tax withholding at an indicated value of $10.22 per share, leaving the reporting person with 232,174 shares beneficially owned after the transactions. The Form 4 shows the reporting person held 201,849 shares before the vesting, which increased to 251,849 upon settlement then decreased due to withholding. This filing documents routine equity compensation vesting and related tax withholding by an executive who is also a director.
InfuSystem Holdings, Inc. filed a current report to share that its President and Chief Executive Officer, Carrie Lachance, and its Chief Financial Officer, Barry Steele, will participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025. The participation was announced in a press release dated September 25, 2025, which is included as Exhibit 99.1 and furnished under Regulation FD, meaning it is provided for information purposes and is not treated as filed for liability purposes. The report also includes an Inline XBRL cover page data file as Exhibit 104.
InfuSystem Holdings insider Scott Shuda reported changes in beneficial ownership. Mr. Shuda, identified as a director, disclosed indirect ownership of 298,383 shares through entities Meridian and BlueLine. He recorded a distribution on 07/07/2025 that reduced holdings by 2,242 shares and a sale on 08/22/2025 of 5,752 shares at an average price of $9.67 (individual sale prices ranged $9.57–$9.83). Following the reported transactions, the filing shows 94,000 shares owned (direct or indirect) after the August sale. The Form 4 notes the sold shares originated from a dissolved partnership and no further sales are planned relating to that partnership.
InfuSystem Holdings, Inc. (INFU) filed a Form 144 notifying an intended open-market sale of 5,752 common shares through Charles Schwab with an aggregate market value of $56,455. The filing states the shares were originally acquired on 08/01/2017 via open-market purchase and payment in cash. The proposed approximate sale date is 08/22/2025, and the filing reports 20,425,964 shares outstanding for the issuer. No securities of the issuer were reported sold by the same person in the past three months. The filer affirms they are not aware of any undisclosed material adverse information.
AWM Investment Company, Inc. filed an amendment to Schedule 13G reporting beneficial ownership of 1,272,296 shares of InfuSystem Holdings, Inc. common stock, representing 6.1% of the outstanding class. AWM states it is the investment adviser to Special Situations Life Sciences Fund, L.P. (SSLS) and holds sole voting and sole dispositive power over the shares held by SSLS. The filing discloses Delaware organization for AWM, the issuer's principal office in Rochester Hills, Michigan, and confirms the stake was acquired and is held in the ordinary course of business, not for the purpose of changing control.